Chemical Structure
6-ECDCA [459789-99-2]
AG-CR1-3560
CAS Number459789-99-2
Product group Chemicals
Estimated Purity>95% (NMR)
Molecular Weight420.6
Overview
- SupplierAdipoGen Life Sciences
- Product Name6-ECDCA [459789-99-2]
- Delivery Days Customer10
- CAS Number459789-99-2
- CertificationResearch Use Only
- Estimated Purity>95% (NMR)
- Hazard InformationNon-hazardous
- Molecular FormulaC26H44O4
- Molecular Weight420.6
- Scientific DescriptionChemical. CAS: 459789-99-2. Formula: C26H44O4. MW: 420.6. Potent and selective FXR agonist (EC50= 99nM). Induces SHP in HSCs to suppress TIMP-1 expression. Apoptosis inducer. Protects against liver fibrosis development in rat in vivo. Displays anticholeretic activity in rat in vivo. Promotes preadipocyte differentiation. Regulates adipogenesis and insulin signaling in vivo. Inhibits vascular smooth muscle cell inflammation and migration. - Potent and selective farnesoid X receptor FXR agonist (EC50= 99nM) [1]. Induces SHP in HSCs to suppress TIMP-1 expression [2]. Apoptosis inducer [2]. Protects against liver fibrosis development in rat in vivo [2]. Displays anticholeretic activity in rat in vivo [3]. Promotes preadipocyte differentiation [4]. Regulates adipogenesis and insulin signaling in vivo [4]. Inhibits vascular smooth muscle cell inflammation and migration [5].
- SMILES[H][C@@]12C[C@H](O)CC[C@]1(C)C1CC[C@]3(C)[C@H](CCC3C1[C@H](O)[C@@H]2CC)[C@H](C)CCC(O)=O
- Storage Instruction2°C to 8°C,-20°C
- UNSPSC12352200
References
- 6r-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity: R. Pellicciari, et al.; J. Med. Chem. 45, 3569 (2002)
- A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 314, 584 (2005)
- Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 313, 604 (2005)
- The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo: G. Rizzo, et al.; Mol. Pharmacol. 70, 1164 (2006)
- Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration: Y.T. Li, et al.; Arterioscler. Thromb. Vasc. Biol. 27, 2606 (2007)